News

US FDA approves Insmed's drug as first treatment for a chronic lung disease

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...
GlobalData on MSN8h

Insmed wins FDA approval for future blockbuster Brinsupri

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...
pharmaphorum10h

Insmed gets first FDA approval for bronchiectasis

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...
BioSpace7h

Insmed Wins Approval For First Bronchiectasis Drug and DPP1 Blocker

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease

The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated’s (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic ...

Insmed gains US approval of lung disease drug forecast to be blockbuster

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

First drug to treat bronchiectasis lung condition approved by FDA

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

Bridgewater firm's stock jumps after FDA approves its new lung disease drug

BRIDGEWATER – Shares of Insmed, a pharmaceutical firm at the intersection of Route 202-206 and Allen Road, jumped 8% on the NASDAQ after the federal Food and Drug Administration approved the company's ...

FDA Approves First Drug for Chronic Lung Condition Bronchiectasis

"For the first time, we have a treatment that directly targets neutrophilic inflammation and addresses a root cause of ...
The Pharma Letter10h

FDA approves Brinsupri for chronic inflammatory lung condition

The US Food and Drug Administration approved New Jersey, USA-based Insmed’s (Nasdaq: INSM) fibrosis bronchiectasis (NCFB), a ...
STAT7h

Pharmalittle: We’re reading about FDA OK for a lung disease drug, pharma sales in China, and more

Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to what could be a ...
Stocktwits on MSN16h

Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic

Insmed shares got a wave of bullish calls Tuesday after U.S. regulators cleared its new drug Brinsupri, the first treatment ...